Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Landon BV, Boland JL, Wahner Hendrickson AE, Armstrong DK, Winterhoff B, Wehr J, Annapragada AV, Cherry C, Balan A, Kaleka G, Velculescu VE, Baylin SB, Zahnow CA, Slamon DJ, Konecny GE, Anagnostou V, Glaspy JA. Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial. Commun Med (Lond). 2026 Feb 6. doi: 10.1038/s43856-026-01404-0. Epub ahead of print. PMID: 41652014.


Related Posts